Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(3.00)
# 1,402
Out of 4,935 analysts
489
Total ratings
41.15%
Success rate
0.03%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Buy | $27 → $20 | $5.90 | +238.98% | 28 | Aug 6, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $31 | $14.60 | +112.33% | 1 | Aug 6, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $105 → $115 | $45.95 | +150.27% | 25 | Aug 5, 2025 | |
| ARGX argenx SE | Maintains: Buy | $720 → $774 | $661.83 | +16.95% | 40 | Aug 1, 2025 | |
| ALKS Alkermes | Reiterates: Neutral | $46 | $26.71 | +72.22% | 24 | Jul 21, 2025 | |
| IRON Disc Medicine | Reiterates: Buy | $118 | $58.06 | +103.24% | 16 | Jul 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Reiterates: Buy | $81 | $26.85 | +201.68% | 24 | Jun 27, 2025 | |
| ROIV Roivant Sciences | Reiterates: Buy | $18 | $11.49 | +56.66% | 20 | Jun 18, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $25 | $1.36 | +1,738.24% | 26 | Jun 11, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Buy | $80 | $51.06 | +56.68% | 33 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $53 | $33.43 | +58.54% | 5 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.82 | +752.72% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.81 | +140.96% | 17 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $16.41 | +107.19% | 16 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $14.77 | +28.64% | 4 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.92 | +525.00% | 17 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $4.63 | +288.77% | 14 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 | $15.46 | +229.88% | 22 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.46 | +1,132.88% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 | $14.74 | +266.35% | 14 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $57 | $24.38 | +133.85% | 26 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $11.45 | +31.06% | 15 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.76 | +184.09% | 14 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $3 | $1.90 | +57.89% | 16 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $3.92 | +104.08% | 9 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $0.70 | +51,109.10% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $1.06 | +842.24% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $158.44 | +14.87% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $7.60 | +146.71% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $28.10 | -35.94% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $16.37 | -51.13% | 7 | Jun 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $52 | $25.20 | +106.35% | 2 | Jun 11, 2019 |
Evolus
Aug 6, 2025
Maintains: Buy
Price Target: $27 → $20
Current: $5.90
Upside: +238.98%
Rapport Therapeutics
Aug 6, 2025
Initiates: Buy
Price Target: $31
Current: $14.60
Upside: +112.33%
Praxis Precision Medicines
Aug 5, 2025
Maintains: Buy
Price Target: $105 → $115
Current: $45.95
Upside: +150.27%
argenx SE
Aug 1, 2025
Maintains: Buy
Price Target: $720 → $774
Current: $661.83
Upside: +16.95%
Alkermes
Jul 21, 2025
Reiterates: Neutral
Price Target: $46
Current: $26.71
Upside: +72.22%
Disc Medicine
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $58.06
Upside: +103.24%
Crinetics Pharmaceuticals
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $26.85
Upside: +201.68%
Roivant Sciences
Jun 18, 2025
Reiterates: Buy
Price Target: $18
Current: $11.49
Upside: +56.66%
Cabaletta Bio
Jun 11, 2025
Reiterates: Buy
Price Target: $25
Current: $1.36
Upside: +1,738.24%
Protagonist Therapeutics
Jun 3, 2025
Reiterates: Buy
Price Target: $80
Current: $51.06
Upside: +56.68%
May 13, 2025
Reiterates: Buy
Price Target: $53
Current: $33.43
Upside: +58.54%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $0.82
Upside: +752.72%
Apr 28, 2025
Reiterates: Buy
Price Target: $14
Current: $5.81
Upside: +140.96%
Apr 23, 2025
Reiterates: Buy
Price Target: $34
Current: $16.41
Upside: +107.19%
Apr 3, 2025
Reiterates: Buy
Price Target: $19
Current: $14.77
Upside: +28.64%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.92
Upside: +525.00%
Mar 20, 2025
Reiterates: Buy
Price Target: $18
Current: $4.63
Upside: +288.77%
Mar 19, 2025
Reiterates: Buy
Price Target: $51
Current: $15.46
Upside: +229.88%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $1.46
Upside: +1,132.88%
Mar 4, 2025
Reiterates: Buy
Price Target: $54
Current: $14.74
Upside: +266.35%
Mar 3, 2025
Reiterates: Buy
Price Target: $57
Current: $24.38
Upside: +133.85%
Feb 27, 2025
Reiterates: Buy
Price Target: $15
Current: $11.45
Upside: +31.06%
Feb 26, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.76
Upside: +184.09%
Feb 18, 2025
Maintains: Buy
Price Target: $30 → $3
Current: $1.90
Upside: +57.89%
Nov 7, 2024
Reiterates: Buy
Price Target: $8
Current: $3.92
Upside: +104.08%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $0.70
Upside: +51,109.10%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $1.06
Upside: +842.24%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $158.44
Upside: +14.87%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $7.60
Upside: +146.71%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $28.10
Upside: -35.94%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $16.37
Upside: -51.13%
Jun 11, 2019
Initiates: Overweight
Price Target: $52
Current: $25.20
Upside: +106.35%